<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-id journal-id-type="hwp">ehj</journal-id><journal-title-group><journal-title>European Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25079365</article-id><article-id pub-id-type="pmc">4320321</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehu272</article-id><article-id pub-id-type="publisher-id">ehu272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group subj-group-type="heading"><subject>Acute Coronary Syndromes</subject></subj-group></subj-group><series-title>Editor's choice</series-title></article-categories><title-group><article-title>The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Morton</surname><given-names>Allison C.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="author-notes" rid="AN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Rothman</surname><given-names>Alexander M. K.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="author-notes" rid="AN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Greenwood</surname><given-names>John P.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gunn</surname><given-names>Julian</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chase</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Alistair S.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fox</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Foley</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Banya</surname><given-names>Winston</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Duolao</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Flather</surname><given-names>Marcus D.</given-names></name><xref ref-type="aff" rid="af7">7</xref><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Crossman</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="af10">10</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="af1"><label>1</label><addr-line>Department of Cardiology</addr-line>, <institution>Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust</institution>, <addr-line>Sheffield</addr-line>, <country>UK</country></aff><aff id="af2"><label>2</label><addr-line>Department of Cardiovascular Science</addr-line>, <institution>University of Sheffield</institution>, <addr-line>Sheffield</addr-line>, <country>UK</country></aff><aff id="af3"><label>3</label><addr-line>Academic Unit of Cardiovascular Medicine</addr-line>, <institution>Yorkshire Heart Centre</institution>, <addr-line>Leeds</addr-line>, <country>UK</country></aff><aff id="af4"><label>4</label><institution>Abertawe Bro Morgannwg University NHS Trust</institution>, <institution>Morriston Hospital</institution>, <addr-line>Swansea</addr-line>, <country>UK</country></aff><aff id="af5"><label>5</label><institution>Institute of Cardiovascular Sciences</institution>, <institution>University of Manchester</institution>, <addr-line>Manchester</addr-line>, <country>UK</country></aff><aff id="af6"><label>6</label><institution>Royal Infirmary of Edinburgh and University of Edinburgh</institution>, <addr-line>Edinburgh</addr-line>, <country>UK</country></aff><aff id="af7"><label>7</label><institution>Royal Brompton and Harefield NHS Foundation Trust and Imperial College London</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af8"><label>8</label><addr-line>Department of Clinical Sciences</addr-line>, <institution>Liverpool School of Tropical Medicine</institution>, <addr-line>Liverpool</addr-line>, <country>UK</country></aff><aff id="af9"><label>9</label><addr-line>Norwich Medical School</addr-line>, <institution>University of East Anglia</institution>, <addr-line>Norwich</addr-line> NR4 7TJ, <country>UK</country></aff><aff id="af10"><label>10</label><addr-line>School of Medicine, University of St Andrews</addr-line>, <institution>KY16 9TF</institution>, <country>UK</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: +44 1334 463502, +44 1334 463597, Fax: +44 1334 463482, Email: <email>dcc7@st-andrews.ac.uk</email></corresp><fn id="AN1" fn-type="con"><label>&#x02020;</label><p>Joint first authors.</p></fn></author-notes><pub-date pub-type="ppub"><day>07</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>4</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>36</volume><issue>6</issue><issue-title>Focus Issue on acute coronary syndromes and intervention</issue-title><fpage>377</fpage><lpage>384</lpage><history><date date-type="received"><day>11</day><month>11</month><year>2013</year></date><date date-type="rev-recd"><day>21</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement><copyright-year>2014</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ehu272.pdf"/><abstract><sec><title>Aims</title><p>Acute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel-response to injury. ACS patients have raised serum markers of inflammation. We hypothesized that if IL-1 is a driving influence of inflammation in non-ST elevation ACS (NSTE-ACS), IL-1 inhibition would reduce the inflammatory response at the time of ACS.</p></sec><sec><title>Methods and results</title><p>A phase II, double-blinded, randomized, placebo-controlled, study recruited 182 patients with NSTE-ACS, presenting &#x0003c;48 h from onset of chest pain. Treatment was 1:1 allocation to daily, subcutaneous IL-1receptor antagonist (IL-1ra) or placebo for 14 days. Baseline characteristics were well matched. Treatment compliance was 85% at 7 days. The primary endpoint (area-under-the-curve for C-reactive protein over the first 7 days) was: IL-1ra group, 21.98 mg day/L (95%CI 16.31&#x02013;29.64); placebo group, 43.5 mg day/L (31.15&#x02013;60.75) (geometric mean ratio = 0.51 mg/L; 95%CI 0.32&#x02013;0.79; <italic>P</italic> = 0.0028). In the IL-1ra group, 14-day achieved high-sensitive C-reactive protein (<italic>P</italic> &#x0003c; 0.0001) and IL-6 levels (<italic>P</italic> = 0.02) were lower than Day 1. Sixteen days after discontinuation of treatment (Day 30) high-sensitive C-reactive protein levels had risen again in the IL-1ra group [IL-1ra; 3.50 mg/L (2.65&#x02013;4.62): placebo; 2.21 mg/L (1.67&#x02013;2.92), <italic>P</italic> = 0.022]. MACE at Day 30 and 3 months was similar but at 1 year there was a significant excess of events in the IL-1ra group.</p></sec><sec><title>Conclusion</title><p>IL-1 drives C-reactive protein elevation at the time of NSTE-ACS. Following 14 days IL-1ra treatment inflammatory markers were reduced. These results show the importance of IL-1 as a target in ACS, but also indicate the need for additional studies with anti-IL-1 therapy in ACS to assess duration and safety.</p></sec><sec><title>Clinical Trial Registration</title><p>EUCTR: 2006-001767-31-GB: <uri xlink:type="simple" xlink:href="www.clinicaltrialsregister.eu/ctr-search/trial/2006-001767-31/GB">www.clinicaltrialsregister.eu/ctr-search/trial/2006-001767-31/GB</uri>.</p></sec></abstract><kwd-group><kwd>Myocardial infarction</kwd><kwd>Drugs</kwd><kwd>Interleukins</kwd></kwd-group></article-meta></front><body><p><related-article id="d35e400" related-article-type="article-reference" ext-link-type="doi" xlink:href="10.1093/eurheartj/ehu369"><bold>See page 337 for the editorial comment on this article (doi:10.1093/eurheartj/ehu369)</bold></related-article></p><sec sec-type="intro" id="s1"><title>Introduction</title><p>Acute coronary syndromes (ACSs) are common conditions that account for about 15% of all deaths and cause considerable morbidity among survivors. Coronary plaque destabilization, and thus presentation of ACS, is associated with inflammation in the vessel wall<sup><xref rid="EHU272C1" ref-type="bibr">1</xref>&#x02013;<xref rid="EHU272C3" ref-type="bibr">3</xref></sup> and a systemic inflammatory response. However, it is unknown whether specific anti-inflammatory treatments modify ACS-associated inflammation and subsequent clinical events.</p><p>Interleukin-1 (IL-1) is a cytokine at the start of the innate inflammatory response, released mainly from macrophages and monocytes, which transduces signals from bacterial products through pattern recognition receptors, complement activation, and TNF&#x003b1;.<sup><xref rid="EHU272C4" ref-type="bibr">4</xref></sup> IL-1 is implicated in arterial wall inflammation in atherosclerosis and is viewed as a therapeutically tractable system. IL-1 is expressed in the vessels of humans with coronary atherosclerosis.<sup><xref rid="EHU272C5" ref-type="bibr">5</xref>,<xref rid="EHU272C6" ref-type="bibr">6</xref></sup> Vessel wall IL-1 increases after balloon injury,<sup><xref rid="EHU272C7" ref-type="bibr">7</xref></sup> and inhibition of IL-1 is associated with reduced neointima formation in a variety of experimental models.<sup><xref rid="EHU272C8" ref-type="bibr">8</xref></sup> In Apo-E deficient mice interleukin-1 receptor antagonist (IL-1ra) inhibits the formation of intimal fatty streaks<sup><xref rid="EHU272C9" ref-type="bibr">9</xref></sup> and genetic deletion of the IL-1 receptor is associated with a reduction in atherosclerosis in response to fat feeding.<sup><xref rid="EHU272C10" ref-type="bibr">10</xref></sup></p><p>C-reactive protein rises following ACS and elevation of C-reactive protein is associated with future cardiovascular events.<sup><xref rid="EHU272C11" ref-type="bibr">11</xref>&#x02013;<xref rid="EHU272C16" ref-type="bibr">16</xref></sup> IL-1 induces IL-6 production,<sup><xref rid="EHU272C16" ref-type="bibr">16</xref></sup> both of which stimulate hepatocyte production of C-reactive protein. Serum levels of IL-6 are elevated in patients with ACS<sup><xref rid="EHU272C17" ref-type="bibr">17</xref></sup> and an elevation is an independent marker of increased mortality in ACS.<sup><xref rid="EHU272C18" ref-type="bibr">18</xref></sup> Thus IL-1 may act as a driver of ACS and the associated inflammatory response. IL-1 signalling can be blocked in man by human recombinant IL-1 receptor antagonist (IL-1ra).<sup><xref rid="EHU272C4" ref-type="bibr">4</xref></sup> The main objective of this study was to examine the effect of IL-1ra given for 14 days upon high-sensitive C-reactive protein levels in patients with non-ST elevation ACS (NSTE-ACS).</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>The aims and methods of the MRC ILA Heart Study have been described in detail previously and the protocol and statistical analysis plan are available in the online appendix.<sup><xref rid="EHU272C19" ref-type="bibr">19</xref></sup> The protocol and statistical analysis plan are available in the online appendix. In brief, this was a randomized, double blind, placebo-controlled multi-centre clinical trial evaluating the effect of a 14-day regimen of IL-1ra on high-sensitive C-reactive protein level after NSTE-ACS. Additional outcomes of interest were levels of von Willebrand factor (vWF), IL-6, troponin, infarct size estimated by cardiac magnetic resonance (CMR) and burden of ischaemia by continuous ECG monitoring. Patients were recruited from five UK hospitals from the cardiac and medical admission wards. The study protocol complies with the Declaration of Helsinki. Ethical approval was obtained from the nationally approved Leeds West Research Ethics Committee and each centre obtained local specific ethical approval. All patients gave fully informed written consent to participate. The study complied with regulatory requirements of the European Union. Adverse events were reviewed by experienced staff blinded to treatment allocation to verify classification and potential association with treatment. An independent data safety monitoring board reviewed safety data throughout the study.</p></sec><sec id="s2b"><title>Participants</title><p>Eligible patients had typical cardiac chest pain &#x0003c;48 h from onset of symptoms, ECG changes of ischaemia, and an elevated troponin prior to randomization. The main exclusion criteria were ST elevation on the ECG, need for immediate reperfusion, or prior revascularization.</p></sec><sec id="s2c"><title>Randomization and masking</title><p>Eligible patients were randomly assigned in a 1:1 ratio using a central 24 h telephone system, stratified by study centre to receive either a 14-day supply of the recombinant IL-1ra Anakinra (Kineret&#x02122; from Amgen) or matching placebo. Qualified research personnel were masked to treatment and remained so from the time of randomization. Patients were taught to administer their own injections, but in cases where this was not possible, injections were administered by health professionals or trained family members.</p></sec><sec id="s2d"><title>Procedures</title><p>After randomization, either 100 mg of Anakinra or 100 mg of placebo was injected subcutaneously once daily in the morning into the abdomen or thigh. Other drugs were left to the treating physicians' discretion. Blood was drawn prior to the injection of study drug at the same time each day (&#x000b1;2h), daily for 7 days and then at Days 14 and 30. Measurements were: high-sensitive C-reactive protein at baseline, Days 1&#x02013;7, 14, and 30; troponin and full blood count at baseline, 1&#x02013;7, and Day 14; creatinine, electrolytes, liver function tests at baseline, Days 1&#x02013;7 and 14; IL-6 and vWF at baseline, Days 1&#x02013;3, Days 14 and 30. Patients were followed-up for 30 days. For measurement of high-sensitive c-reactive protein, troponin, Vwf, and IL-6, blood samples were processed and then frozen at &#x02212;80&#x000b0;C before transportation on dry ice in batches to the core laboratories.</p><p>ST Holter Monitor Sub-study: between Days 2 and 4 post-randomization, patients at one centre (Sheffield) underwent three lead, continuous ECG monitoring for 24 h. These were analysed by an automated algorithm for ST-segment deviation, and independently reviewed by a blinded cardiac physiologist and a physician (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>). Cardiac Magnetic Resonance Sub-study: Patients at one centre (Leeds) were scheduled for baseline CMR imaging during their index admission with a follow-up study at 30 days, using an identical imaging protocol (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>).</p><p>The primary endpoint was the log-transformed area-under-the-curve (AUC) of serum high-sensitive C-reactive protein over the first 7 days. Secondary endpoints included high-sensitive C-reactive protein at 7, 14, and 30 days, log transformed AUC of Troponin-I, vWF and IL-6, total duration of ST-segment depression on Holter monitoring, myocardial scar, area at risk, and left-ventricular function determined by CMR. The cumulative incidence of major adverse cardiovascular events (MACE) including death, stroke, and new myocardial infarction were recorded at 30 days, 3 months, and 12 months.</p></sec><sec id="s2e"><title>Sample size and statistical analysis</title><p>To detect a relative reduction of one-third in the high-sensitive C-reactive protein AUC between the treatment and the placebo groups, which was the reduction seen in IL-1ra treatment of rheumatoid arthritis at this dose (Amgen data on file), with 80% power at a 5% level of significance required 80 patients in each group (<italic>n</italic> = 160) based upon the log-transformed value of the area under the curve of high-sensitive C-reactive protein and a standardized difference [difference/ standard deviation (D)] of &#x0223c;0.45. To allow for data loss of 10% in each arm and two interim analyses, a final sample size of 184 patients was projected with a <italic>P</italic>-value of &#x0003c;0.045 considered significant.<sup><xref rid="EHU272C20" ref-type="bibr">20</xref></sup> Patients with at least four follow-up measurements of high-sensitive C-reactive protein were included in the primary analysis on an intention-to-treat basis and missing data was imputed using a Markov Chain Monte Carlo (MCMC) simulation method.<sup><xref rid="EHU272C21" ref-type="bibr">21</xref></sup> A Student's <italic>t</italic>-test was used to estimate the treatment effect (in form of geometric mean ratios) for the primary endpoint and some secondary endpoints. The time-to-event endpoints were compared using the log-rank test. Other serious adverse events were analysed using a Fisher exact test. All analyses were done using Stata version 10.1 and SAS version 9.1.3.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>A total of 182 patients (93 IL-1ra treated, 89 placebo) were recruited at five UK centres between July 2007 and March 2010 and followed for 1 year. Patient flow through the study is summarized in <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHU272F1">1</xref></italic>.<sup><xref rid="EHU272C19" ref-type="bibr">19</xref></sup> Baseline characteristics were well matched between the two groups (<italic>Table&#x000a0;<xref ref-type="table" rid="EHU272TB1">1</xref></italic>). The mean age was 61 years, there was an excess of males, and 26% had prior MI. In-hospital revascularization rates were similar between groups (<italic>Table&#x000a0;<xref ref-type="table" rid="EHU272TB4">4</xref></italic>). The patients were well treated with contemporary therapy; at 14 days 95% were taking aspirin, 90% clopidogrel, 95% statins, and 80% ACE-inhibitors or angiotensin receptor blockers. Patients were randomized within 48 h from onset of chest pain and there was no difference in time from onset of chest pain to first dose between group (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>). In total, 85% of patients in the IL-1ra group and 84% in the placebo group received all 7 daily doses of treatment and 81 and 84%, respectively, continued treatment up to 14 days (all comparisons non-significant). Over two-thirds of patients successfully self-injected medication upon discharge home (no difference between groups), the remaining patients medication being administered by the nursing team. The reasons for non-compliance to treatment are shown in the <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>.
<table-wrap id="EHU272TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Active (<italic>n</italic> = 93)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 89)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), mean (SD)</td><td rowspan="1" colspan="1">61.4 (11.7)</td><td rowspan="1" colspan="1">61.3 (12.3)</td><td rowspan="1" colspan="1">0.9556</td></tr><tr><td rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">63 (67.7)</td><td rowspan="1" colspan="1">67 (75.3)</td><td rowspan="1" colspan="1">0.3249</td></tr><tr><td rowspan="1" colspan="1">White British, (%)</td><td rowspan="1" colspan="1">89 (95.7)</td><td rowspan="1" colspan="1">82 (92.1)</td><td rowspan="1" colspan="1">0.6845</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">30.0 (7.1)</td><td rowspan="1" colspan="1">28.4 (4.7)</td><td rowspan="1" colspan="1">0.0687</td></tr><tr><td rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1">131.4 (20.7)</td><td rowspan="1" colspan="1">126.5 (16.7)</td><td rowspan="1" colspan="1">0.0795</td></tr><tr><td rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1">75.2 (12.5)</td><td rowspan="1" colspan="1">74.3 (11.3)</td><td rowspan="1" colspan="1">0.6063</td></tr><tr><td colspan="4" rowspan="1">Current smoking, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Current</td><td rowspan="1" colspan="1">34 (36.6)</td><td rowspan="1" colspan="1">31 (34.8)</td><td rowspan="4" colspan="1">0.4140</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Ex</td><td rowspan="1" colspan="1">34 (36.6)</td><td rowspan="1" colspan="1">27 (30.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Never</td><td rowspan="1" colspan="1">24 (25.8)</td><td rowspan="1" colspan="1">31 (34.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;NA</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1">Previous MI, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">23 (24.7)</td><td rowspan="1" colspan="1">24 (27.0)</td><td rowspan="1" colspan="1">0.9313</td></tr><tr><td rowspan="1" colspan="1">Prior stroke, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">3 (3.4)</td><td rowspan="1" colspan="1">0.3600</td></tr><tr><td rowspan="1" colspan="1">Prior TIA, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">8 (8.6)</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">0.0769</td></tr><tr><td rowspan="1" colspan="1">Family history of IHD, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">48 (51.6)</td><td rowspan="1" colspan="1">47 (52.8)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">31 (33.3)</td><td rowspan="1" colspan="1">29 (32.6)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">Hyperlipidaemia, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">27 (29.0)</td><td rowspan="1" colspan="1">28 (31.5)</td><td rowspan="1" colspan="1">0.9344</td></tr><tr><td colspan="4" rowspan="1">IDDM, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Insulin dependent</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="5" colspan="1">0.0876</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-insulin dependent</td><td rowspan="1" colspan="1">7 (7.5)</td><td rowspan="1" colspan="1">6 (6.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diet controlled</td><td rowspan="1" colspan="1">6 (6.5)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;No history</td><td rowspan="1" colspan="1">77 (82.8)</td><td rowspan="1" colspan="1">81 (91.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;NA</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p>NA, not applicable; MI, myocardial infarction.</p></fn></table-wrap-foot></table-wrap>
<fig id="EHU272F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Consort flow diagram detailing the number of participants who were randomly assigned and followed-up for the duration of the study up to 1 year.</p></caption><graphic xlink:href="ehu27201"/></fig></p><p>As pre-specified in the statistical analysis plan, only patients with four or more readings of high-sensitive C-reactive protein were included in the primary outcome analysis. Ten patients in the IL-1ra group and 12 in the placebo group had &#x0003c;4 readings, these patients were excluded from the primary outcome analysis. high-sensitive C-reactive protein over the first 7 days are shown in <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHU272F2">2</xref></italic>. high-sensitive C-reactive protein levels were similar on the first 2 days of treatment but then diverged with suppression in the IL-1ra group. The high-sensitive C-reactive protein AUC for the first 7 days in the IL-1ra group was 21.98 mg day/L (95%CI 16.31&#x02013;29.64) and 43.50 mg day/L (31.15&#x02013;60.75) in the placebo group, with the geometric mean ratio between IL-1ra and placebo being 0.51 (95% CI: 0.32&#x02013;0.79), <italic>P</italic> = 0.0028 (<italic>Table&#x000a0;<xref ref-type="table" rid="EHU272TB2">2</xref></italic> and <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHU272F2">2</xref></italic>). This suggests that IL-1ra reduced high-sensitive C-reactive protein AUC by almost half over the first 7 days. The significant difference in absolute levels seen at Day 7 was maintained at Day 14. <italic>Table&#x000a0;<xref ref-type="table" rid="EHU272TB3">3</xref></italic> shows routine blood results at baseline and Day 14. There was a statistically significant suppression of white cell count throughout treatment but no overt neutropaenia.
<table-wrap id="EHU272TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Primary and secondary outcome results</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char="." span="1"/><col align="char" char=" " span="1"/><col align="left" span="1"/><col align="char" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Outcome</th><th align="center" colspan="2" rowspan="1">Active<hr/></th><th align="center" colspan="2" rowspan="1">Placebo<hr/></th><th align="center" colspan="2" rowspan="1">Treatment effect<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"><italic>n</italic></th><th align="left" rowspan="1" colspan="1">GM (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>n</italic></th><th align="left" rowspan="1" colspan="1">GM (95% CI)</th><th align="left" rowspan="1" colspan="1">GM Ratio (95% CI)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Imputed high-sensitive C-reactive protein AUC (Days 1&#x02013;7, mg.day/L)<sup>a</sup></td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">21.98 (16.31, 29.64)</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">43.50 (31.15, 60.75)</td><td rowspan="1" colspan="1">0.51 (0.32, 0.79)</td><td rowspan="1" colspan="1">0.0028</td></tr><tr><td rowspan="1" colspan="1">High-sensitive C-reactive protein at Day 1 (mg/L)</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">5.38 (4.12, 7.04)</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">5.21 (3.75, 7.22)</td><td rowspan="1" colspan="1">1.03 (0.68, 1.57)</td><td rowspan="1" colspan="1">0.88</td></tr><tr><td rowspan="1" colspan="1">High-sensitive C-reactive protein at Day 7 (mg/L)</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">1.53 (1.12, 2.11)</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">6.77 (4.92, 9.31)</td><td rowspan="1" colspan="1">0.25 (0.15, 0.35)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">High-sensitive C-reactive protein at Day 14 (mg/L)</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">1.74 (1.28, 2.39)</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">4.60 (3.21, 6.59)</td><td rowspan="1" colspan="1">0.38 (0.24, 0.61)</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td rowspan="1" colspan="1">High-sensitive C-reactive protein at Day 30 (mg/L)</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">3.50 (2.65, 4.62)</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">2.21 (1.67, 2.92)</td><td rowspan="1" colspan="1">1.58 (1.07, 2.34)</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">Imputed troponin AUC (Days 1&#x02013;7, &#x003bc;g.day/L)</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">3.23 (2.15, 4.87)</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">3.83 (2.46, 5.96)</td><td rowspan="1" colspan="1">0.84 (0.46, 1.54)</td><td rowspan="1" colspan="1">0.58</td></tr><tr><td rowspan="1" colspan="1">Troponin at Day 1 (&#x003bc;g/L)</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">0.97 (0.63, 1.49)</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">1.25 (0.79, 1.97)</td><td rowspan="1" colspan="1">0.77 (0.41, 1.45)</td><td rowspan="1" colspan="1">0.42</td></tr><tr><td rowspan="1" colspan="1">Troponin at Day 7 (&#x003bc;g/L)</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">0.12 (0.08, 0.18)</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">0.14 (0.09, 0.23)</td><td rowspan="1" colspan="1">0.83 (0.43, 1.56)</td><td rowspan="1" colspan="1">0.55</td></tr><tr><td rowspan="1" colspan="1">Troponin at Day 14 (&#x003bc;g/L)</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">0.025 (0.017, 0.036)</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">0.026 (0.016, 0.041)</td><td rowspan="1" colspan="1">0.96 (0.54, 1.69)</td><td rowspan="1" colspan="1">0.88</td></tr><tr><td rowspan="1" colspan="1">Troponin at Day 30 (&#x003bc;g/L)</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">0.014 (0.001, 0.021)</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">0.012 (0.007, 0.018)</td><td rowspan="1" colspan="1">1.23 (0.71, 2.11)</td><td rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1">Imputed vWF AUC (Days 1&#x02013;3, IU.day/mL)</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">2.98 (2.75, 3.22)</td><td rowspan="1" colspan="1">84</td><td rowspan="1" colspan="1">3.04 (2.83, 3.27)</td><td rowspan="1" colspan="1">0.98 (0.88, 1.09)</td><td rowspan="1" colspan="1">0.68</td></tr><tr><td rowspan="1" colspan="1">vWF at Day 1 (IU/mL)</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">1.45 (1.34, 1.56)</td><td rowspan="1" colspan="1">84</td><td rowspan="1" colspan="1">1.43 (1.32, 1.54)</td><td rowspan="1" colspan="1">1.01 (0.91, 3.39)</td><td rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">vWF at Day 14 (IU/mL)</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">1.35 (1.24, 1.47)</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">1.41 (1.29, 1.54)</td><td rowspan="1" colspan="1">0.96 (0.85, 1.08)</td><td rowspan="1" colspan="1">0.48</td></tr><tr><td rowspan="1" colspan="1">vWF at Day 30 (IU/mL)</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">1.39 (1.28, 1.51)</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">1.38 (1.26, 1.53)</td><td rowspan="1" colspan="1">1.01 (0.89, 1.14)</td><td rowspan="1" colspan="1">0.92</td></tr><tr><td rowspan="1" colspan="1">Imputed IL-6 AUC (Days 1&#x02013;3, pg.day/mL)</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">8.24 (6.71, 10.11)</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">12.32 (9.66, 15.73)</td><td rowspan="1" colspan="1">0.67 (0.49, 0.92)</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">IL-6 at Day 1 (pg/mL)</td><td rowspan="1" colspan="1">86</td><td rowspan="1" colspan="1">6.01 (4.68, 7.72)</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">5.23 (3.98, 6.88)</td><td rowspan="1" colspan="1">1.15 (0.80, 1.66)</td><td rowspan="1" colspan="1">0.45</td></tr><tr><td rowspan="1" colspan="1">IL-6 at Day 14 (pg/mL)</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">2.51 (2.04, 3.08)</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">3.82 (2.82, 5.16)</td><td rowspan="1" colspan="1">0.66 (0.46, 0.94)</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">IL-6 at Day 30 (pg/mL)</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">3.38 (2.80, 4.16)</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">2.88 (2.38, 3.49)</td><td rowspan="1" colspan="1">1.18 (0.90, 1.56)</td><td rowspan="1" colspan="1">0.22</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><p><sup>a</sup>Primary outcome excludes patients with &#x0003c;4 high-sensitive C-reactive protein readings.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="EHU272TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Routine blood results at baseline and Day 14</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" colspan="3" rowspan="1">Baseline<hr/></th><th align="center" colspan="3" rowspan="1">Day 14<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Active (<italic>n</italic> = 93)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 89)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Active (<italic>n</italic> = 85)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 79)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Haemogloblin (g/dL)</td><td rowspan="1" colspan="1">14.18 &#x000b1; 1.46</td><td rowspan="1" colspan="1">14.31 &#x000b1; 1.44</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">13.65 &#x000b1; 1.41</td><td rowspan="1" colspan="1">13.35 &#x000b1; 1.48</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">White cell count (&#x000d7;10<sup>9</sup>/L)</td><td rowspan="1" colspan="1">9.16 &#x000b1; 2.61</td><td rowspan="1" colspan="1">8.87 &#x000b1; 2.35</td><td rowspan="1" colspan="1">0.44</td><td rowspan="1" colspan="1">7.13 &#x000b1; 1.70</td><td rowspan="1" colspan="1">7.78 &#x000b1; 1.91</td><td rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">Platelets (&#x000d7;10<sup>9</sup>/L)</td><td rowspan="1" colspan="1">266.92 &#x000b1; 63.77</td><td rowspan="1" colspan="1">269.70 &#x000b1; 99.44</td><td rowspan="1" colspan="1">0.82</td><td rowspan="1" colspan="1">268.81 &#x000b1; 75.18</td><td rowspan="1" colspan="1">299.17 &#x000b1; 86.91</td><td rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="1" colspan="1">Urea (mmol/L)</td><td rowspan="1" colspan="1">5.56 &#x000b1; 1.76</td><td rowspan="1" colspan="1">5.43 &#x000b1; 1.89</td><td rowspan="1" colspan="1">0.64</td><td rowspan="1" colspan="1">6.19 &#x000b1; 2.25</td><td rowspan="1" colspan="1">5.39 &#x000b1; 2.21</td><td rowspan="1" colspan="1">0.028</td></tr><tr><td rowspan="1" colspan="1">Creatinine (&#x000b5;mol/L)</td><td rowspan="1" colspan="1">91.14 &#x000b1; 17.71</td><td rowspan="1" colspan="1">92.05 &#x000b1; 24.91</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1">96.59 &#x000b1; 20.59</td><td rowspan="1" colspan="1">93.42 &#x000b1; 25.18</td><td rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Sodium (mmol/L)</td><td rowspan="1" colspan="1">138.07 &#x000b1; 2.98</td><td rowspan="1" colspan="1">138.00 &#x000b1; 2.96</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">138.89 &#x000b1; 3.05</td><td rowspan="1" colspan="1">138.24 &#x000b1; 3.80</td><td rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="1" colspan="1">Potassium mmol/L)</td><td rowspan="1" colspan="1">4.16 &#x000b1; 0.32</td><td rowspan="1" colspan="1">4.22 &#x000b1; 0.37</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">4.39 &#x000b1; 0.28</td><td rowspan="1" colspan="1">4.45 &#x000b1; 0.40</td><td rowspan="1" colspan="1">0.32</td></tr><tr><td rowspan="1" colspan="1">eGFR (mL/min)</td><td rowspan="1" colspan="1">73.36 &#x000b1; 15.86</td><td rowspan="1" colspan="1">75.06 &#x000b1; 21.20</td><td rowspan="1" colspan="1">0.55</td><td rowspan="1" colspan="1">69.96 &#x000b1; 15.48</td><td rowspan="1" colspan="1">74.25 &#x000b1; 19.71</td><td rowspan="1" colspan="1">0.14</td></tr><tr><td rowspan="1" colspan="1">Aspartate transaminase (IU/L)</td><td rowspan="1" colspan="1">35.30 (30.74, 40.53)</td><td rowspan="1" colspan="1">36.56 (30.97, 43.15)</td><td rowspan="1" colspan="1">0.74</td><td rowspan="1" colspan="1">25.82 (23.73, 28.10)</td><td rowspan="1" colspan="1">22.51 (20.86, 24.29)</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">Alkaline transaminase (IU/L)<sup>a</sup></td><td rowspan="1" colspan="1">26.34 (23.66, 29.32)</td><td rowspan="1" colspan="1">25.92 (23.39, 28.73)</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">29.09 (25.91, 32.67)</td><td rowspan="1" colspan="1">23.64 (21.48, 26.02)</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">Alkaline phosphatise (IU/L)<sup>a</sup></td><td rowspan="1" colspan="1">96.77 (86.02, 108.88)</td><td rowspan="1" colspan="1">88.27 (78.80, 98.88)</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">88.93 (78.27, 101.04)</td><td rowspan="1" colspan="1">88.80 (77.75, 101.42)</td><td rowspan="1" colspan="1">0.99</td></tr><tr><td rowspan="1" colspan="1">Total bilirubin (&#x000b5;mol/L)</td><td rowspan="1" colspan="1">11.04 (10.05, 12.13)</td><td rowspan="1" colspan="1">12.28 (11.07, 13.62)</td><td rowspan="1" colspan="1">0.13</td><td rowspan="1" colspan="1">11.11 &#x000b1; 4.99</td><td rowspan="1" colspan="1">10.71 &#x000b1; 5.34</td><td rowspan="1" colspan="1">0.65</td></tr><tr><td rowspan="1" colspan="1">CK (IU/L)</td><td rowspan="1" colspan="1">147.28 (110.46, 196.36)</td><td rowspan="1" colspan="1">199.04 (156.50, 253.14)</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">CKMB (&#x000b5;g/L)<sup>a</sup></td><td rowspan="1" colspan="1">5.44 (3.57, 8.28)</td><td rowspan="1" colspan="1">4.83 (3.01, 7.78)</td><td rowspan="1" colspan="1">0.71</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Troponin I (&#x000b5;g/L)<sup>a</sup></td><td rowspan="1" colspan="1">1.40 (0.94, 2.10)</td><td rowspan="1" colspan="1">2.42 (1.58, 3.71)</td><td rowspan="1" colspan="1">0.07</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Troponin T (&#x000b5;g/L)<sup>a,b</sup></td><td rowspan="1" colspan="1">0.15 (0.05, 0.52)</td><td rowspan="1" colspan="1">0.27 (0.11, 0.67)</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="TN3"><p><sup>a</sup>Geometric mean (95% CI).</p></fn><fn id="TN4"><p><sup>b</sup><italic>n</italic> = 17; 8 active, 9 placebo.</p></fn></table-wrap-foot></table-wrap>
<fig id="EHU272F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Geometric mean of high sensitivity C-reactive protein over the first 7 days of treatment with IL-1ra or placebo (95% CI) calculated for primary outcome analysis.</p></caption><graphic xlink:href="ehu27202"/></fig></p><p>At Day 30, an increase in the absolute high-sensitive C-reactive protein from Day 14 in the IL-1ra treated group to 3.50 mg/L (2.65&#x02013;4.62) was seen. This is in contrast to placebo treatment where high-sensitive C-reactive protein continued to decline to 2.21 mg/L (1.67&#x02013;2.92). This resulted in a significant difference between groups at Day 30.</p><p>There were no differences in troponin AUC (Days 1&#x02013;7) or any absolute measures of troponin (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online, <italic>Figure</italic></ext-link>). The AUC of IL-6 (Days 1&#x02013;3) in the IL-1ra group was 8.24 pg day/mL (6.71&#x02013;0.11) and in the placebo group was 12.32 pg/mL (9.66&#x02013;15.73) <italic>P</italic> = 0.012. IL-6 levels remained suppressed by IL-1ra at Day 14 but by Day 30 there was no significant difference between groups. There were no significant differences in any vWF measurements.</p><p>Clinical outcomes, MACE, and adverse events are summarized in <italic>Table&#x000a0;<xref ref-type="table" rid="EHU272TB4">4</xref></italic> and <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHU272F3">3</xref></italic>. As expected, there was a significant increase in injection site reactions in the IL-1ra treated group (26 compared with 4% with placebo, <italic>P</italic> &#x0003c; 0.0001). There was no significant difference in MACE at 30 days or 3 months. Although this study was not powered for the analysis of clinical outcomes, at 1 year there was a significant increase in MACE in the IL-1ra treated group, driven by a non-significant increase in recurrent myocardial infarction.
<table-wrap id="EHU272TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Summary statistics for analysis of MACE and other serious adverse events</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Active (<italic>n</italic> = 93)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 89)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Time-to-event analysis<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;MACE at 30 days</td><td rowspan="1" colspan="1">3 (46.4)</td><td rowspan="1" colspan="1">2 (32.2)</td><td rowspan="1" colspan="1">0.6800</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MACE at 3 months</td><td rowspan="1" colspan="1">7 (38.0)</td><td rowspan="1" colspan="1">2 (10.7)</td><td rowspan="1" colspan="1">0.0980</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MACE at 1 year</td><td rowspan="1" colspan="1">13 (18.9)</td><td rowspan="1" colspan="1">4 (5.4)</td><td rowspan="1" colspan="1">0.0233</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Death</td><td rowspan="1" colspan="1">5 (6.8)</td><td rowspan="1" colspan="1">2 (2.7)</td><td rowspan="1" colspan="1">0.2440</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MI</td><td rowspan="1" colspan="1">8 (11.4)</td><td rowspan="1" colspan="1">2 (2.7)</td><td rowspan="1" colspan="1">0.0581</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Stroke</td><td rowspan="1" colspan="1">1 (1.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0.3205</td></tr><tr><td colspan="4" rowspan="1">Event analysis<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;All bleeds</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Neutropaenia</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Serious infection</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Revascularization</td><td rowspan="1" colspan="1">84 (90.3)</td><td rowspan="1" colspan="1">76 (85.4)</td><td rowspan="1" colspan="1">0.3664</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Any (-cath only)</td><td rowspan="1" colspan="1">60 (64.5)</td><td rowspan="1" colspan="1">54 (60.7)</td><td rowspan="1" colspan="1">0.6468</td></tr><tr><td rowspan="1" colspan="1">&#x02003;CABG only</td><td rowspan="1" colspan="1">3 (3.2)</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">0.6212</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cath and CABG</td><td rowspan="1" colspan="1">4 (4.3)</td><td rowspan="1" colspan="1">5 (5.6)</td><td rowspan="1" colspan="1">0.7431</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cath and PCI</td><td rowspan="1" colspan="1">53 (57.0)</td><td rowspan="1" colspan="1">48 (53.9)</td><td rowspan="1" colspan="1">0.7656</td></tr><tr><td rowspan="1" colspan="1">&#x02003;PCI only</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cath only</td><td rowspan="1" colspan="1">28 (30.1)</td><td rowspan="1" colspan="1">26 (29.2)</td><td rowspan="1" colspan="1">1.0000</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Injection site reactions</td><td rowspan="1" colspan="1">24 (25.8)</td><td rowspan="1" colspan="1">4 (4.5)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other SAE</td><td rowspan="1" colspan="1">30 (32.3)</td><td rowspan="1" colspan="1">21 (23.6)</td><td rowspan="1" colspan="1">0.2478</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cardiac</td><td rowspan="1" colspan="1">19 (20.4)</td><td rowspan="1" colspan="1">14 (15.7)</td><td rowspan="1" colspan="1">0.4463</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Non-cardiac</td><td rowspan="1" colspan="1">15 (16.1)</td><td rowspan="1" colspan="1">7 (7.9)</td><td rowspan="1" colspan="1">0.1120</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Unable to specify</td><td rowspan="1" colspan="1">2 (2.2)</td><td rowspan="1" colspan="1">5 (5.6)</td><td rowspan="1" colspan="1">0.2704</td></tr></tbody></table><table-wrap-foot><fn id="TN5"><p>MACE, major adverse cardiovascular event; NA, not applicable.</p></fn><fn id="TN6"><p><sup>a</sup><italic>P</italic>-value was calculated from log-rank test. Number of patients with events (incidence rate/100) is presented.</p></fn><fn id="TN7"><p><sup>b</sup><italic>P</italic>-value was calculated from Fisher exact test. Number of patients with events (%) is presented.</p></fn></table-wrap-foot></table-wrap>
<fig id="EHU272F3" position="float"><label>Figure&#x000a0;3</label><caption><p>Kaplan&#x02013;Meier event curves for major adverse cardiovascular events, death, myocardial infarction, and stroke by treatment.</p></caption><graphic xlink:href="ehu27203"/></fig></p><p>There were no significant differences between groups in either of the ST segment Holter or CMR sub-studies (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>).</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This is the first randomized trial to investigate the effects of a specific inhibitor of interleukin-1 (IL-1ra, Anakinra) in the NSTE-ACS and demonstrates powerful suppression of markers of inflammation in this condition. Widespread coronary inflammatory activation has become the established mechanism of ACS.<sup><xref rid="EHU272C22" ref-type="bibr">22</xref>,<xref rid="EHU272C23" ref-type="bibr">23</xref></sup> The link between this paradigm and blood-based markers of inflammation has been suggested by a number of studies, often based on secondary analysis of large trials of a variety of therapeutic compounds,<sup><xref rid="EHU272C12" ref-type="bibr">12</xref></sup> and a 30- patient pilot study investigating the effect of IL-1RA on cardiac remodelling post-STEMI showed a significant reduction in high-sensitive C-reactive protein at 72 h.<sup><xref rid="EHU272C24" ref-type="bibr">24</xref></sup> These studies have suggested that relative elevations of high-sensitive C-reactive protein, IL-6, and vWF, among others, may predict a number of adverse outcomes plausibly linked to continued coronary inflammation.<sup><xref rid="EHU272C12" ref-type="bibr">12</xref>,<xref rid="EHU272C17" ref-type="bibr">17</xref>,<xref rid="EHU272C18" ref-type="bibr">18</xref>,<xref rid="EHU272C25" ref-type="bibr">25</xref></sup> Prospective studies are based mainly in the stable population where small elevations of high-sensitive C-reactive protein appear to predict continued risk of AMI and other CV events although this effect may be small.<sup><xref rid="EHU272C15" ref-type="bibr">15</xref>,<xref rid="EHU272C26" ref-type="bibr">26</xref></sup> Others, looking specifically at the time of ACS, have not seen a predictive property of high-sensitive C-reactive protein.<sup><xref rid="EHU272C27" ref-type="bibr">27</xref></sup></p><p>This study indicates that IL-1 drives a significant part of the elevation of high-sensitive C-reactive protein that occurs at the time of NSTE-ACS. The study has examined the treatment effect on high-sensitive C-reactive protein in two ways: the AUC of high-sensitive C-reactive protein (up to Day 7) reflecting total high-sensitive C-reactive protein production in this time, and achieved high-sensitive C-reactive protein at Day 14 (patients were prepared to self-inject for 14 days, but had daily samples drawn for only 7 days). high-sensitive C-reactive protein was rapidly suppressed into the normal range in treated patients and was persistently lower than in the control group for the duration of therapy with IL-1ra. Since, IL-1ra has no known functions other than blockade of the IL-1 signalling receptor and is highly effective therapy in IL-1 driven auto-inflammatory syndromes, these data strongly suggest the importance of IL-1 as a driving influence on inflammation in these patients.</p><p>At the time of discontinuation of IL-1ra at 14 days high-sensitive C-reactive protein was suppressed, suggesting inhibition of inflammation, but by Day 30, high-sensitive C-reactive protein levels rose in the IL-1ra treated group, whereas those in the placebo group continued to fall resulting in a significant difference between the groups at 30 days. This indicates a loss of the IL-1ra mediated inhibition of inflammation. These results suggest that either the inflammatory events around the time of NSTE-ACS may continue beyond Day 14 and/or that IL-1-stimulated inflammation may normally drive its own later resolution. Both explanations are plausible. IL-1 receptor occupation leads to a number of events that are associated with either latent IL-1 expression that is not translated or IL-1 production that is not released. It is also possible that withdrawal of IL-1 receptor inhibition leads to increased sensitivity to IL-1 via the loss of endogenous IL1-ra normally driven by IL-1 receptor stimulation.</p><p>IL-1ra therapy was in general very well tolerated. There was the expected increase in injection site reactions with the treatment and a mild but significant lowering of the white cell count, which is presumably the withdrawal of IL-1 mediated white cell survival effects.<sup><xref rid="EHU272C28" ref-type="bibr">28</xref></sup> This study was not powered for clinical endpoints, however, the MACE composite endpoint at 1 year showed an increase in events in the IL-1ra-treated group. This may be for a number of reasons including pharmacological issues (dose and duration of therapy), or biological consequences of IL-1 inhibition that impairs natural healing driving the late MACE, but this will need to be explored in other appropriately designed studies. Considerable caution, however, should be given to the validity of these MACE observations because of power limitations.</p><p>IL-1ra therapy was without effect upon infarct size, as measured by troponin and CMR (see <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material online</ext-link>). There is debate from studies using experimental models of the effect of IL-1 inhibition on infarct size. Our results do not support a reduction in infarct size by IL-1ra in the NSTE-ACS patients we studied, but do not exclude either an effect in more extensive or full-thickness myocardial infarction as may occur in ST elevation ACS. The findings suggest that the effects of IL-1ra are not due to a reduction in infarct size but there is a reduction of the associated inflammation. Whether the inflammatory stimulus derives from the plaque or the myocardium is unknown and unexplored in this study.</p><p>This study has some important limitations, which have become apparent given the results. The most obvious is that treatment was given for only one duration&#x02014;14 days&#x02014;and our data suggest that a longer duration would have been be desirable. The treatment was given as early as possible but as this was a trial requiring consent, we cannot exclude a difference in results if the IL-1ra had been given immediately by the study team. The size of infarcts is certainly not large, as shown in the CMR substudy. A bigger infarct may have given more opportunity for an effect on infarct size modulation. The study was not powered for late events and as a result we have very few details on the nature of these late events that give rise to the apparent excess MACE at 1 year.</p><p>These results, therefore, give both encouragement and potential warning for the use of IL-1 inhibition in patients with coronary artery disease that has presented as ACS. We show that IL-1 is certainly an important mediator of the inflammation at the time of NSTE-ACS and this trial met its primary endpoint. The duration of treatment and perhaps dose and timing of treatment with this inhibitor in ACS may, however, be critical. These results indicate that treatment for 14 days is insufficient to achieve durable suppression of inflammation following discontinuation of the drug. Our results have also indicated the possibility of an increased rate of late re-infarction following a 2-week period of IL-1 inhibition. This demands further study as IL-1 is so clearly an important mediator in ACS as shown by our results. The large prospective study of long-term IL-1 inhibition in patients with CAD in the CANTOS<sup><xref rid="EHU272C29" ref-type="bibr">29</xref></sup> study will throw more light on this important area, but additional studies around the time of ACS are now urgently needed.</p></sec><sec id="s5"><title>Statement on analysis error of this manuscript</title><p>In July 2010, the preliminary results for the MRC-ILA-HEART Study were prepared and disseminated to authors for review. The Chief Investigator queried the results on the basis of the equivalence of injection site reaction rate with the Clinical Trials and Evaluation Unit (CTEU) in September 2010, which was re-checked and verified by the study statistician. A manuscript was subsequently prepared but was never published. In July 2012, the Chief Investigator requested an audit of the study results, which was undertaken in August 2012. This identified a simple yet critical error in the linkage of the randomization list with the patient ID list which produced an incorrect result. When the analysis was repeated with the correct data, the primary endpoint of the trial had been met as reported here. An abstract of the incorrect data was published (<uri xlink:type="simple" xlink:href="http://heart.bmj.com/content/97/Suppl_1/A13.1">http://heart.bmj.com/content/97/Suppl_1/A13.1</uri>) but the error has been notified by Heart.</p><p>A subsequent investigation led by the Chair of the trial Data Monitoring Committee in August 2012 confirmed the simple but critical error in the linkage with the randomization list and recommended the re-analysis of the data by the study statistician and also an independent re-analysis by a second statistician. The Trial Steering Committee in a meeting in November 2012 endorsed this course of action. Therefore, D.W. was appointed to conduct an independent analysis of the data. The findings of D.W. were consistent with the revised analysis by the study statistician and it is this verified data that is reported in this manuscript.</p></sec><sec id="s6"><title>Supplementary material</title><p><ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehu272/-/DC1">Supplementary material is available at <italic>European Heart Journal</italic> online</ext-link>.</p></sec><sec id="s7"><title>Funding</title><p>This work was supported by <funding-source>UK Medical Research Council Experimental Medicine</funding-source> Grant number <award-id>G0502131</award-id> and a <funding-source>UK Medical Research Council Clinical Research Training</funding-source> Fellowship <award-id>MR/K002406/1</award-id> (A.M.K.R.). IL-1ra (Anakinra) and matching placebo were donated by Amgen Corporation. Funding to pay the Open Access publication charges for this article was provided by the University of Sheffield.</p><p><bold>Conflict of interest:</bold> D.C.C. has received grant funding from Novartis.</p></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful to all the patients who agreed to participate in this study and all the health professionals who took part.</p></ack><ref-list><title>References</title><ref id="EHU272C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms of acute coronary syndromes and their implications for therapy</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>2004</fpage><lpage>2013</lpage><pub-id pub-id-type="pmid">23697515</pub-id></element-citation></ref><ref id="EHU272C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Atherosclerosis &#x02013; an inflammatory disease</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">9887164</pub-id></element-citation></ref><ref id="EHU272C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><article-title>Atherosclerosis: the road ahead review</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>503</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">11239408</pub-id></element-citation></ref><ref id="EHU272C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name></person-group><article-title>Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases</article-title><source>Nat Rev Drug Discov</source><year>2012</year><volume>11</volume><fpage>633</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">22850787</pub-id></element-citation></ref><ref id="EHU272C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Gadsdon</surname><given-names>P</given-names></name><name><surname>Holden</surname><given-names>H</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><name><surname>Holt</surname><given-names>CM</given-names></name></person-group><article-title>Interleukin-1 beta in coronary arteries of patients with ischemic heart disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1996</year><volume>16</volume><fpage>1000</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">8696938</pub-id></element-citation></ref><ref id="EHU272C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satterthwaite</surname><given-names>G</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><name><surname>Suvarna</surname><given-names>K</given-names></name><name><surname>Blakemore</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Braddock</surname><given-names>M</given-names></name><name><surname>Crossman</surname><given-names>D</given-names></name></person-group><article-title>Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><fpage>488</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">16169330</pub-id></element-citation></ref><ref id="EHU272C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>J</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>S</given-names></name><name><surname>Holt</surname><given-names>C</given-names></name><name><surname>Crossman</surname><given-names>D</given-names></name></person-group><article-title>Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries</article-title><source>Cardiovasc Res</source><year>1999</year><volume>44</volume><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">10615399</pub-id></element-citation></ref><ref id="EHU272C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Dewberry</surname><given-names>R</given-names></name><name><surname>Dower</surname><given-names>S</given-names></name><name><surname>Crossman</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>S</given-names></name></person-group><article-title>Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice</article-title><source>Am J Pathol</source><year>2006</year><volume>168</volume><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">16565512</pub-id></element-citation></ref><ref id="EHU272C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhage</surname><given-names>R</given-names></name><name><surname>Maret</surname><given-names>A</given-names></name><name><surname>Pieraggi</surname><given-names>MT</given-names></name><name><surname>Thiers</surname><given-names>JC</given-names></name><name><surname>Arnal</surname><given-names>JF</given-names></name><name><surname>Bayard</surname><given-names>F</given-names></name></person-group><article-title>Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice</article-title><source>Circulation</source><year>1998</year><volume>97</volume><fpage>242</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">9462524</pub-id></element-citation></ref><ref id="EHU272C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>S</given-names></name><name><surname>Brookes</surname><given-names>Z</given-names></name><name><surname>Shaw</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Alp</surname><given-names>NJ</given-names></name><name><surname>Dower</surname><given-names>S</given-names></name><name><surname>Crossman</surname><given-names>DC</given-names></name></person-group><article-title>Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><fpage>e5073</fpage><pub-id pub-id-type="pmid">19347044</pub-id></element-citation></ref><ref id="EHU272C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>Biasucci</surname><given-names>LM</given-names></name><name><surname>Gallimore</surname><given-names>JR</given-names></name><name><surname>Grillo</surname><given-names>RL</given-names></name><name><surname>Rebuzzi</surname><given-names>AG</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">7880233</pub-id></element-citation></ref><ref id="EHU272C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Morrow</surname><given-names>D</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>LM</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>C-reactive protein levels and outcomes after statin therapy</article-title><source>N Eng J Med</source><year>2005</year><volume>352</volume><fpage>20</fpage><lpage>28</lpage></element-citation></ref><ref id="EHU272C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group><article-title>C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction</article-title><source>Circulation</source><year>1998</year><volume>97</volume><fpage>2007</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">9610529</pub-id></element-citation></ref><ref id="EHU272C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name></person-group><article-title>Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">12432042</pub-id></element-citation></ref><ref id="EHU272C15"><label>15</label><element-citation publication-type="journal"><collab>Emerging Risk Factors Collaboration</collab><article-title>C-reactive protein, fibrinogen, and cardiovascular disease prediction</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1310</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">23034020</pub-id></element-citation></ref><ref id="EHU272C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>R</given-names></name><name><surname>Mancilla</surname><given-names>J</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Ghorbani</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>SC</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF</article-title><source>Blood</source><year>1990</year><volume>75</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">2294996</pub-id></element-citation></ref><ref id="EHU272C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijm</surname><given-names>J</given-names></name><name><surname>Wikby</surname><given-names>A</given-names></name><name><surname>Tompa</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>AG</given-names></name><name><surname>Jonasson</surname><given-names>L</given-names></name></person-group><article-title>Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><fpage>452</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">15695127</pub-id></element-citation></ref><ref id="EHU272C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasucci</surname><given-names>LM</given-names></name><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>Fantuzzi</surname><given-names>G</given-names></name><name><surname>Caligiuri</surname><given-names>G</given-names></name></person-group><article-title>Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>2079</fpage><lpage>2084</lpage><pub-id pub-id-type="pmid">10217645</pub-id></element-citation></ref><ref id="EHU272C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crossman</surname><given-names>DC</given-names></name><name><surname>Morton</surname><given-names>AC</given-names></name><name><surname>Gunn</surname><given-names>JP</given-names></name><name><surname>Greenwood</surname><given-names>JP</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Lucking</surname><given-names>AJ</given-names></name><name><surname>Flather</surname><given-names>MD</given-names></name><name><surname>Lees</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>CE</given-names></name></person-group><article-title>Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)</article-title><source>Trials</source><year>2008</year><volume>9</volume><fpage>8</fpage><pub-id pub-id-type="pmid">18298837</pub-id></element-citation></ref><ref id="EHU272C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>PC</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name></person-group><article-title>A multiple testing procedure for clinical trials</article-title><source>Biometrics</source><year>1979</year><volume>35</volume><fpage>549</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">497341</pub-id></element-citation></ref><ref id="EHU272C21"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>J</given-names></name></person-group><source>Analysis of Incomplete Multivariate Data</source><year>1997</year><publisher-loc>New York</publisher-loc><publisher-name>Chapman and Hall</publisher-name></element-citation></ref><ref id="EHU272C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Inflammation in atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2012</year><volume>32</volume><fpage>2045</fpage><lpage>2051</lpage><pub-id pub-id-type="pmid">22895665</pub-id></element-citation></ref><ref id="EHU272C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffon</surname><given-names>A</given-names></name><name><surname>Biasucci</surname><given-names>LM</given-names></name><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>D'Onofrio</surname><given-names>G</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Widespread coronary inflammation in unstable angina</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12097534</pub-id></element-citation></ref><ref id="EHU272C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Van Tassell</surname><given-names>BW</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Kontos</surname><given-names>MC</given-names></name><name><surname>Grizzard</surname><given-names>JD</given-names></name><name><surname>Spillman</surname><given-names>DW</given-names></name><name><surname>Oddi</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>CS</given-names></name><name><surname>Melchior</surname><given-names>RD</given-names></name><name><surname>Mueller</surname><given-names>GH</given-names></name><name><surname>Abouzaki</surname><given-names>NA</given-names></name><name><surname>Rengel</surname><given-names>LR</given-names></name><name><surname>Varma</surname><given-names>A</given-names></name><name><surname>Gambill</surname><given-names>ML</given-names></name><name><surname>Falcao</surname><given-names>RA</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Vetrovec</surname><given-names>GW</given-names></name></person-group><article-title>Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]</article-title><source>Am J Cardiol</source><year>2013</year><volume>111</volume><fpage>1394</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">23453459</pub-id></element-citation></ref><ref id="EHU272C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Lison</surname><given-names>L</given-names></name><name><surname>Choussat</surname><given-names>R</given-names></name><name><surname>Ankri</surname><given-names>A</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name><name><surname>Perlemuter</surname><given-names>K</given-names></name><name><surname>Philippe</surname><given-names>F</given-names></name><name><surname>Drobinski</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name></person-group><article-title>Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>36</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">10898421</pub-id></element-citation></ref><ref id="EHU272C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sever</surname><given-names>PS</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Chang</surname><given-names>CL</given-names></name><name><surname>Hingorani</surname><given-names>A</given-names></name><name><surname>Thom</surname><given-names>SA</given-names></name><name><surname>Hughes</surname><given-names>AD</given-names></name><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name></person-group><collab>on behalf of the ASCOT Investigators</collab><article-title>Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">21798891</pub-id></element-citation></ref><ref id="EHU272C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaski</surname><given-names>JC</given-names></name><name><surname>Fern&#x000e1;ndez-Berg&#x000e9;s</surname><given-names>DJ</given-names></name><name><surname>Consuegra-S&#x000e1;nchez</surname><given-names>L</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>JMC</given-names></name><name><surname>Garcia-Moll</surname><given-names>X</given-names></name><name><surname>Mostaza</surname><given-names>JM</given-names></name><name><surname>Cebada</surname><given-names>RT</given-names></name><name><surname>Juanatey</surname><given-names>JRG</given-names></name><name><surname>Martinez</surname><given-names>GG</given-names></name><name><surname>Marrugat</surname><given-names>J</given-names></name></person-group><article-title>A comparative study of biomarkers for risk prediction in acute coronary syndrome&#x02014;results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study</article-title><source>Atherosclerosis</source><year>2010</year><volume>212</volume><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">20619836</pub-id></element-citation></ref><ref id="EHU272C28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Re</surname><given-names>F</given-names></name><name><surname>Muzio</surname><given-names>M</given-names></name><name><surname>Bertini</surname><given-names>R</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>Giri</surname><given-names>JG</given-names></name><name><surname>Dower</surname><given-names>SK</given-names></name><name><surname>Sims</surname><given-names>JE</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>472</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">8332913</pub-id></element-citation></ref><ref id="EHU272C29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>Zalewski</surname><given-names>A</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)</article-title><source>Am Heart J</source><year>2011</year><volume>162</volume><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">21982649</pub-id></element-citation></ref></ref-list></back></article>